The content on this site is intended for healthcare professionals only
Dr Ellis talks to ecancertv at ESMO 2016 about the finding that fulvestrant significantly increased progression-free survival in women with hormone-receptor-positive advanced breast cancer, and particularly those with less aggressive lower-volume disease.
Read the news story for more.
These results were also discussed by Prof John Roberston here.
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC
Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy
OncoAlert round up July 28th to August 3rd, 2023
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Loco-regional management after neoadjuvant chemotherapy
Management of HER2 positive metastatic breast cancer treatment algorithm
Post neoadjuvant management in BRCA mutant breast cancer patients
Elacestrant shows improved PFS in ER-positive/HER2-negative mBC
